Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE2 | O96020 | 1/20 | 0.42 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | NT5E | P21589 | 2/20 | 0.33 |
| ▸ | CDK1 | P06493 | 1/20 | 0.33 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21101450 | 1.00 | CCNE2 (0.42) | CCNE2CCNE1CDK2NT5ECDK1 | |
| SCHEMBL21136340 | 0.91 | CCNE2 (0.34) | CCNE2CCNE1CDK2 | |
| SCHEMBL21101442 | 0.90 | CDK2 (0.47) | CCNE2CCNE1CDK2NT5ECDK1 | |
| SCHEMBL24939854 | 0.89 | CDK1 (0.33) | CCNE1CDK2CDK1 | |
| SCHEMBL21102195 | 0.89 | CDK1 (0.33) | CCNE1CDK2CDK1 | |
| SCHEMBL19644727 | 0.89 | CDK1 (0.33) | CCNE1CDK2CDK1 | |
| SCHEMBL19644903 | 0.81 | NR1I2 (0.43) | CDK2CDK1 | |
| SCHEMBL24939943 | 0.81 | NR1I2 (0.43) | CDK2CDK1 | |
| SCHEMBL21101654 | 0.81 | CDK1 (0.40) | CCNE1CDK2CDK1 | |
| SCHEMBL19644878 | 0.81 | CDK1 (0.40) | CCNE1CDK2CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230017958-A1 | 2'-SUBSTITUTED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR RNA VIRUS TREATMENT | Atea Pharmaceuticals, Inc. (US) | 2023-01-19 | — | — | US | disclosed |
| US-10946033-B2 | 2′-substituted-N6-substituted purine nucleotides for RNA virus treatment | Atea Pharmaceuticals, Inc. (US) | 2021-03-16 | — | — | US | disclosed |
| US-10875885-B2 | β-d-2′-deoxy-2′-α-fluoro-2′-β-c-substituted-2-modified-n6-substituted purine nucleotides for HCV treatment | Atea Pharmaceuticals, Inc. (US) | 2020-12-29 | — | — | US | disclosed |
| US-10815266-B2 | β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment | Atea Pharmaceuticals, Inc. (US) | 2020-10-27 | — | — | US | disclosed |
| US-20200331956-A1 | BETA-D-2'-DEOXY-2'-ALPHA-FLUORO-2'-BETA-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | Atea Pharmaceuticals, Inc. (US) | 2020-10-22 | — | — | US | disclosed |
| US-20190201433-A1 | 2'-SUBSTITUTED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR RNA VIRUS TREATMENT | Atea Pharmaceuticals, Inc. (US) | 2019-07-04 | — | — | US | disclosed |
| US-20190177356-A1 | BETA-D-2'-DEOXY-2'-ALPHA-FLUORO-2'-BETA-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | Atea Pharmaceuticals, Inc. (US) | 2019-06-13 | — | — | US | disclosed |
| US-10239911-B2 | Beta-D-2′-deoxy-2′-alpha-fluoro-2′-beta-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment | Atea Pharmaceuticals, Inc. (US) | 2019-03-26 | — | — | US | disclosed |
| US-10005811-B2 | β-D-2′-deoxy-2′-α-fluoro-2′β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment | Atea Pharmaceuticals, Inc. (US) | 2018-06-26 | — | — | US | disclosed |
| US-10000523-B2 | β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment | Atea Pharmaceuticals, Inc. (US) | 2018-06-19 | — | — | US | disclosed |
| US-20180030081-A1 | BETA-D-2'-DEOXY-2'-ALPHA-FLUORO-2'-BETA-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | Atea Pharmaceuticals, Inc. | 2018-02-01 | — | — | US | disclosed |
| US-20180030082-A1 | BETA-D-2'-DEOXY-2'-ALPHA-FLUORO-2'BETA-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | Atea Pharmaceuticals, Inc. | 2018-02-01 | — | — | US | disclosed |
| US-9828410-B2 | β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment | Atea Pharmaceuticals, Inc. (US) | 2017-11-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10005811-B2 | β-D-2′-deoxy-2′-α-fluoro-2′β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment | NSUN2, PNP, NUDT1 | CCNE2 4192/4885CCNE1 4304/4885CDK2 2178/4885 |
| US-10239911-B2 | Beta-D-2′-deoxy-2′-alpha-fluoro-2′-beta-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment | NSUN2, NUDT1, PNP | CCNE2 3250/4885CCNE1 3517/4885CDK2 1730/4885 |
| US-10946033-B2 | 2′-substituted-N6-substituted purine nucleotides for RNA virus treatment | NSUN2, ADAR, NSUN3 | CCNE2 3448/4885CCNE1 3485/4885CDK2 1258/4885 |
| US-20180030081-A1 | BETA-D-2'-DEOXY-2'-ALPHA-FLUORO-2'-BETA-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | NSUN2, NUDT1, DCTD | CCNE2 3057/4885CCNE1 3354/4885CDK2 1661/4885 |
| US-20200331956-A1 | BETA-D-2'-DEOXY-2'-ALPHA-FLUORO-2'-BETA-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | NSUN2, NUDT1, DCTD | CCNE2 3057/4885CCNE1 3354/4885CDK2 1661/4885 |
| US-10875885-B2 | β-d-2′-deoxy-2′-α-fluoro-2′-β-c-substituted-2-modified-n6-substituted purine nucleotides for HCV treatment | NSUN2, PNP, NUDT1 | CCNE2 3886/4885CCNE1 4041/4885CDK2 1995/4885 |
| US-20190201433-A1 | 2'-SUBSTITUTED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR RNA VIRUS TREATMENT | NSUN2, ADAR, NSUN3 | CCNE2 3313/4885CCNE1 3374/4885CDK2 1333/4885 |
| US-10815266-B2 | β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment | NSUN2, PNP, NUDT1 | CCNE2 3886/4885CCNE1 4041/4885CDK2 1995/4885 |
| US-10000523-B2 | β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment | NSUN2, PNP, NUDT1 | CCNE2 3886/4885CCNE1 4041/4885CDK2 1995/4885 |
| US-20180030082-A1 | BETA-D-2'-DEOXY-2'-ALPHA-FLUORO-2'BETA-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | NSUN2, NUDT1, DCTD | CCNE2 3280/4885CCNE1 3568/4885CDK2 1740/4885 |
| US-20190177356-A1 | BETA-D-2'-DEOXY-2'-ALPHA-FLUORO-2'-BETA-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | NSUN2, NUDT1, DCTD | CCNE2 3057/4885CCNE1 3354/4885CDK2 1661/4885 |
| US-20230017958-A1 | 2'-SUBSTITUTED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR RNA VIRUS TREATMENT | NSUN2, ADAR, NSUN3 | CCNE2 3313/4885CCNE1 3374/4885CDK2 1333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.